8 January 2026 in OTO Open
Objective: Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) have shown remarkable results in glycemic control for patients with type 2 diabetes (T2DM). While no association has been made, there is a concern for thyroid cancer (TC) from GLP‐1RA. We aimed to study the 5‐year risk of TC in T2DM patients taking GLP‐1RA. Study Design: Retrospective cohort. Setting: TriNetX database. Methods: TriNetX was queried to identify T2DM patients between 2017 and 2019. The 5‐year risk of TC in patients using GLP‐1RA was compared to patients taking sodium‐glucose cotransporter 2 inhibitors (SGLT‐2I), metformin, and dipeptidyl peptidase 4 inhibitors (DPP‐4I) after propensity score matching by demographics and comorbidities. Results: On analysis of T2DM patients taking GLP‐1RA compared to SGLT‐2I, 7736 patients were in each cohort after matching. The 5‐year rate of TC in patients taking GLP‐1RA was 0.30% compared to 0.48% in those taking SGLT‐2I (RR 0.62 (95% CI 0.37‐1.05); P = .07). Analysis of GLP‐1RA versus metformin yielded 5158 patients in each cohort. Patients taking GLP‐1RA had similar rates of TC compared to those taking metformin (0.25% vs 0.39%; RR 0.65 (95% CI 0.32‐1.31); P = .22). A comparison of GLP‐1RA versus DPP‐4I yielded 12,570 patients in each cohort. The rate of TC was not increased in those taking GLP‐1RA compared to those taking DPP‐4I (0.33% vs 0.37%; RR 0.91 (0.60‐1.39); P = .67). Conclusion: T2DM patients taking GLP‐1RA may not have an increased 5‐year risk of TC compared to those taking metformin, SGLT‐2I, or DPP‐4I. Conclusions of long‐term use are limited as most GLP‐1RA were approved within the last decade.
30 March 2026 in Ear, Nose & Throat Journal
Objective: YouTube is a video-sharing platform that patients frequently utilize. However, there are no objective assessments of the quality of information about otosclerosis on YouTube. Therefore, we aimed to assess the quality of YouTube videos for patient education via a cross-sectional study. We utilized 4 search phrases and analyzed them with 3 different scoring metrics, followed by statistical analysis. Results: Fifty videos were analyzed for the search terms “stapedectomy,” “stapedotomy,” “laser stapedotomy,” and “otosclerosis.” Most videos for “stapedotomy” (42%) and “otosclerosis” (41.2%) were intended for patients, while those for “stapedotomy” (48%) and “laser stapedotomy” (96%) were created for healthcare professionals or students. Higher modified DISCERN scores were associated with healthcare organization-produced videos for “otosclerosis” ( P = .01964) and “stapedotomy” ( P = .02842). Higher global quality score ( P = .02964) and Journal of the American Medical Society scores ( P = .01488) were significantly associated with videos made by verified users for “otosclerosis.” Conclusion: The quality of YouTube videos may not be sufficient for patient education on stapedectomy and stapedotomy for otosclerosis. Only 2 search terms included most videos geared toward patient education, while the other 2 terms had more videos for healthcare professionals. Lower transparency and reliability scores may give concerns about bias.
26 January 2025 in Otolaryngology–Head and Neck Surgery
Objective: The objective of this study is to examine the risk of hypocalcemia after thyroidectomy in patients taking histamine‐2 receptor antagonists.Study Design: Retrospective cohort study.Setting: Multicenter, single database.Methods: Thirty‐four thousand two hundred eighteen patients treated with total thyroidectomy from 2011 to 2022 were identified via the TriNetX Research Network. We compared the incidence of transient (0‐1 month and 1‐6 months following thyroidectomy) and permanent (6‐12 months following thyroidectomy) postthyroidectomy hypocalcemia in patients with and without H2 receptor antagonists. Propensity score matching and sensitivity analysis were done to control for additional risk factors.Results: Patients were divided into 2 cohorts: those with an H2 receptor antagonist prescription before surgery (n = 5108) and those without (n = 29,110). 44.9% and 11.6% of thyroidectomy patients taking H2 receptor antagonists had hypocalcemia compared to 38.3% and 8.2% of patients without H2 receptor antagonists at 0 to 1 month and 6 to 12 months, respectively. Patients taking H2 receptor antagonists had a significantly increased risk of experiencing hypocalcemia at 0 to 1 month, 1 to 6 months, and 6 to 12 months. Patients taking H2 receptor antagonists were also at increased risk for visiting the emergency department and receiving intravenous calcium replenishment at 1 and 6 months following surgery. Sensitivity analysis continued to yield significant results at all time points.Conclusion: Patients taking H2 receptor antagonists may be at increased risk of short and long‐term hypocalcemia after thyroid surgery. This is the first retrospective cohort study examining the risk of hypocalcemia after thyroidectomy in patients taking H2 receptor antagonists.